Corneal epithelial toxicity of antiglaucoma formulations: in vitro study of repeated applications

about

The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis

P2860

Q24631812-5E9077F6-9426-48CF-865E-8E34D38EFCEA

P2860

Corneal epithelial toxicity of antiglaucoma formulations: in vitro study of repeated applications

Item

http://www.wikidata.org/entity/Q42561376

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Corneal epithelial toxicity of ...... study of repeated applications

@en

Corneal epithelial toxicity of ...... study of repeated applications

@nl

type

Item

label

Corneal epithelial toxicity of ...... study of repeated applications

@en

Corneal epithelial toxicity of ...... study of repeated applications

@nl

prefLabel

Corneal epithelial toxicity of ...... study of repeated applications

@en

Corneal epithelial toxicity of ...... study of repeated applications

@nl

P1476

Corneal epithelial toxicity of ...... study of repeated applications

@en

P2093

Barbara De Servi

http://www.w3.org/2001/XMLSchema#string

Giampiero Cattaneo

http://www.w3.org/2001/XMLSchema#string

Marisa Meloni

http://www.w3.org/2001/XMLSchema#string

P2860

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

Reconstituted human corneal epithelium: a new alternative to the Draize eye test for the assessment of the eye irritation potential of chemicals and cosmetic products.

Short-term effect of topical antiglaucoma medication on tear-film stability, tear secretion, and corneal sensitivity in healthy subjects.

Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost.

Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials.

Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from β-blockers and prostaglandin analogs.

The tight junction: a multifunctional complex.

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial.

Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy.

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy

P304

1433-1440

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OPTH.S35057

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232232249

http://www.w3.org/2001/XMLSchema#string

P698

23055659

http://www.w3.org/2001/XMLSchema#string

P932

3460710

http://www.w3.org/2001/XMLSchema#string

Corneal epithelial toxicity of antiglaucoma formulations: in vitro study of repeated applications

about

P2860

P2860

Corneal epithelial toxicity of antiglaucoma formulations: in vitro study of repeated applications

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P5875

P698

P932